Corporate & Investor Presentation
Improving adherence to therapy with patient monitoring and resupply
ResAdhere: remote monitoring + mask resupply drive improved adherence
In a study of ~100k patients with AirView cloud-connected devices...
Probability on Therapy (%)
100
100%
0
90
Resupply group (AirView + Brightree)
Control group (non-resupply)
Time to Drop out (days)
+ brightree
AirView™
84%
66%
360
...the likelihood of therapy termination decreased by >50% after one year
and there was a significant increase in daily PAP usage
Benjafield, et al. AJRCCM 2018 (abstract)
Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings.
40 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22
ResMedView entire presentation